O4-08-02: Phase 3 Trial of the TAU Aggregation Inhibitor Leuco-Methylthioninium-Bis (Hydromethanesulfonate) (Lmtm) in Mild to Moderate Alzheimer's Disease

Alzheimer s & Dementia ◽

10.1016/j.jalz.2016.06.650 ◽

2016 ◽

Vol 12 ◽

pp. P351-P352 ◽

Cited By ~ 3

Author(s):

Serge Gauthier ◽

Howard H. Feldman ◽

Lon S. Schneider ◽

Gordon Wilcock ◽

Giovanni B. Frisoni ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 3 ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

Neurobiology of Aging ◽

10.1016/j.neurobiolaging.2014.01.128 ◽

2014 ◽

Vol 35 ◽

pp. S26 ◽

Cited By ~ 1

Author(s):

Claude M. Wischik ◽

C.R. Harrington ◽

J.M.D. Storey

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 3 ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

F1-01-02: Rember: Issues in design of a phase 3 disease modifying clinical trial of Tau aggregation inhibitor therapy in Alzheimer's disease

Alzheimer s & Dementia ◽

10.1016/j.jalz.2009.05.175 ◽

2009 ◽

Vol 5 (4S_Part_3) ◽

pp. P74-P74 ◽

Cited By ~ 7

Author(s):

Claude Wischik

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Clinical Trial ◽

Inhibitor Therapy ◽

Phase 3 ◽

Disease Modifying ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(16)31275-2 ◽

2016 ◽

Vol 388 (10062) ◽

pp. 2873-2884 ◽

Cited By ~ 160

Author(s):

Serge Gauthier ◽

Howard H Feldman ◽

Lon S Schneider ◽

Gordon K Wilcock ◽

Giovanni B Frisoni ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Inhibitor Therapy ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Aggregation Inhibitor ◽

Randomised Controlled ◽

Tau Aggregation

Download Full-text

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

Alzheimer s & Dementia ◽

10.1016/j.jalz.2008.05.438 ◽

2008 ◽

Vol 4 ◽

pp. T167-T167 ◽

Cited By ~ 70

Author(s):

Claude M. Wischik ◽

Peter Bentham ◽

Damon J. Wischik ◽

Kwang Meng Seng

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Disease Progression ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

O1-06-04: Methylthioninium chloride (MTC) acts as a Tau aggregation inhibitor (TAI) in a cellular model and reverses Tau pathology in transgenic mouse models of Alzheimer's disease

Alzheimer s & Dementia ◽

10.1016/j.jalz.2008.05.259 ◽

2008 ◽

Vol 4 ◽

pp. T120-T121 ◽

Cited By ~ 13

Author(s):

Charles Harrington ◽

Janet E. Rickard ◽

David Horsley ◽

Kathleen A. Harrington ◽

Kathleen P. Hindley ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Transgenic Mouse ◽

Mouse Models ◽

Cellular Model ◽

Transgenic Mouse Models ◽

Tau Pathology ◽

Methylthioninium Chloride ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer’s Disease

Journal of Pharmacology and Experimental Therapeutics ◽

10.1124/jpet.114.219352 ◽

2014 ◽

Vol 352 (1) ◽

pp. 110-118 ◽

Cited By ~ 67

Author(s):

Thomas C. Baddeley ◽

Jennifer McCaffrey ◽

John M. D. Storey ◽

John K. S. Cheung ◽

Valeria Melis ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Inhibitor Therapy ◽

Aggregation Inhibitor ◽

Tau Aggregation ◽

Redox Forms

Download Full-text

P4-384: Tau Aggregation Inhibitor (TAI) therapy with rember™ changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer's disease (AD)

Alzheimer s & Dementia ◽

10.1016/j.jalz.2008.05.2454 ◽

2008 ◽

Vol 4 ◽

pp. T786-T787 ◽

Cited By ~ 5

Author(s):

Alison D. Murray ◽

Roger T. Staff ◽

Trevor S. Ahearn ◽

Peter Bentham ◽

Kwang Meng Seng ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Glucose Metabolism ◽

Medial Temporal Lobes ◽

Temporal Lobes ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

Tau-aggregation inhibitor therapy for Alzheimer's disease

Biochemical Pharmacology ◽

10.1016/j.bcp.2013.12.008 ◽

2014 ◽

Vol 88 (4) ◽

pp. 529-539 ◽

Cited By ~ 147

Author(s):

Claude M. Wischik ◽

Charles R. Harrington ◽

John M.D. Storey

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Inhibitor Therapy ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

P4-347: Tau aggregation inhibitor (TAI) therapy with rember™ arrests the trajectory of rCBF decline in brain regions affected by Tau pathology in mild and moderate Alzheimer's disease (AD)

Alzheimer s & Dementia ◽

10.1016/j.jalz.2008.05.2417 ◽

2008 ◽

Vol 4 ◽

pp. T775-T775 ◽

Cited By ~ 6

Author(s):

Roger T. Staff ◽

Trevor S. Ahearn ◽

Alison D. Murray ◽

Peter Bentham ◽

Kwang Meng Seng ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Brain Regions ◽

Tau Pathology ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text

Chapter 11. Rationale for Tau-Aggregation Inhibitor Therapy in Alzheimer's Disease and Other Tauopathies

Drug Discovery - Emerging Drugs and Targets for Alzheimer's Disease ◽

10.1039/9781849731065-00210 ◽

2010 ◽

pp. 210-232 ◽

Cited By ~ 1

Author(s):

Claude M. Wischik ◽

Damon J. Wischik ◽

John M.D. Storey ◽

Charles R. Harrington

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Inhibitor Therapy ◽

Aggregation Inhibitor ◽

Tau Aggregation

Download Full-text